Genprex, Inc.
$1.16
▼
-2.53%
2026-04-21 07:07:01
www.genprex.com
NCM: GNPX
Explore Genprex, Inc. stock price, valuation, financial statements, dividend history, analyst estimates, and long-term business fundamentals on StockSifting.
Market Cap
$10.45 M
Current Price
$1.16
52W High / Low
$55 / $1.15
Stock P/E
—
Book Value
$3.78
Dividend Yield
—
ROCE
-194.32%
ROE
-3.39%
Face Value
—
EPS
$-17.4
Exp Qtr EPS
—
Sector
Healthcare
Industry
Biotechnology
Employees
13
Beta
-0.67
Debt / Equity
—
Current Ratio
3.84
Quick Ratio
3.84
Forward P/E
-0.53
Price / Sales
—
Enterprise Value
$2.57 M
EV / EBITDA
-0.17
EV / Revenue
—
Rating
None
Target Price
—
EPS Forecast (FY)
—
Pros
- Short-term liquidity looks comfortable.
- Valuation is not stretched on P/E basis.
Cons
- Return on equity is on the weaker side.
- Capital efficiency is modest.
- Operating margin is thin.
- Net margin is relatively low.
Sift Stocks
| S.No. | Name | Price | P.E. | Market Cap | Div Yld % | ROCE | ROE | 52Week High/ Low | Book Value |
|---|---|---|---|---|---|---|---|---|---|
| 1. | Tempest Therapeutics, Inc. | $1.94 | — | $27.83 M | — | -195.16% | -2.04% | $12.23 / $1.5 | $1.35 |
| 2. | Spyre Therapeutics, Inc. | $73.39 | — | $5.76 B | — | -30.53% | -25.17% | $75 / $12.25 | $7.16 |
| 3. | Aktis Oncology, Inc. | $20.83 | — | $1.08 B | — | -31.96% | -29.45% | $29.16 / $14.72 | $-159.68 |
| 4. | Clearmind Medicine Inc. | $1.14 | — | $2.38 M | — | -475.2% | -1.2% | $52.4 / $0.59 | $5.49 |
| 5. | Quince Therapeutics, Inc. | $1.27 | — | $22.33 M | — | -33.74% | -2.48% | $45.5 / $0.8 | $0.02 |
| 6. | Dermata Therapeutics, Inc. | $1.34 | — | $5.47 M | — | -124.91% | -1.94% | $9.9 / $1.1 | $2.34 |
| 7. | Nkarta, Inc. | $3.49 | — | $247.38 M | — | -31.94% | -28.9% | $3.48 / $1.63 | $4.39 |
Quarterly Results
Figures shown in M / B
| Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | |
|---|---|---|---|---|---|---|
| Sales | 0 M | 0 M | 0 M | 0 M | 0 M | — |
| Operating Profit | -3.52 M | -3.35 M | -4.68 M | -3.97 M | -4.34 M | — |
| Net Profit | -3.79 M | -3.8 M | -4.67 M | -3.96 M | -4.33 M | — |
| EPS in Rs | -0.42 | -0.42 | -0.52 | -0.44 | -0.48 | -61.65 |
Profit & Loss
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Sales | 0 M | 0 M | 0 M | 0 M |
| Operating Profit | -15.52 M | -21.17 M | -31.06 M | -23.83 M |
| Net Profit | -16.23 M | -21.11 M | -30.86 M | -23.74 M |
| EPS in Rs | -1.79 | -2.33 | -3.41 | -2.62 |
Balance Sheet
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Total Assets | 10.16 M | 4.12 M | 10.67 M | 25.09 M |
| Total Liabilities | 2.2 M | 2.5 M | 3.25 M | 2.81 M |
| Equity | 7.96 M | 1.62 M | 7.42 M | 22.27 M |
| Current Assets | 8.36 M | 2.08 M | 7.53 M | 21.47 M |
| Current Liabilities | 2.17 M | 2.5 M | 3.25 M | 2.81 M |
Cash Flow
Last available yearly cash flow history
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Operating CF | -15.31 M | -17.92 M | -24.74 M | -17.62 M |
| Investing CF | 0 M | 0.77 M | -0.07 M | -0.06 M |
| Financing CF | 21.54 M | 12.01 M | 10.59 M | 0.01 M |
| Free CF | -15.31 M | -17.92 M | -24.81 M | -17.68 M |
| Capex | — | — | -0.07 M | -0.06 M |
5Y Margin & Growth History
Last 5 year derived history from yfinance annual statements
| 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|
| Revenue Growth % | — | — | — | — |
| Earnings Growth % | 31.59% | -29.99% | — | — |
| Profit Margin % | — | — | — | — |
| Operating Margin % | — | — | — | — |
| Gross Margin % | — | — | — | — |
| EBITDA Margin % | — | — | — | — |
Dividend & Split History
Latest dividend and stock split events stored from yfinance
Dividend History
No dividend history available.
Stock Splits
| Date | Split |
|---|---|
| 2025-10-21 | 1:0.02 |
| 2024-02-02 | 1:0.025 |